White R H, McCurdy S A, von Marensdorff H, Woodruff D E, Leftgoff L
University of California, Davis Medical Center, Sacramento.
Ann Intern Med. 1989 Nov 1;111(9):730-7. doi: 10.7326/0003-4819-111-9-730.
To evaluate the efficacy and accuracy of monitoring prothrombin times at home.
Randomized, prospective cohort study.
Outpatients discharged from a university hospital or a community hospital.
Fifty patients started on warfarin for the first time who demonstrated an ability to use the monitor and who had not achieved a stable response to warfarin in the hospital.
Oral anticoagulation therapy managed using a portable prothrombin time monitor compared with specialized anticoagulation clinic care.
In the 46 patients who completed the 8-week study, the median percentage of time that patients in the home-monitor group (n = 23) were within a range equal to the target prothrombin ratio +/- 0.3, but always above 1.25, was 93%, compared with 75% for patients in the clinic group (n = 23) (P = 0.003). There was no significant difference between groups in the percentage of time above the therapeutic range; however, the percentage of time that patients were subtherapeutic was significantly greater in the clinic group (P less than 0.001). There were no major thromboembolic or hemorrhagic complications in either group. Differences between home monitor measurements and corresponding clinical laboratory measurements using blood samples drawn within 4 hours of the home test were comparable to differences observed between measurements using two different clinical laboratory instruments.
Use of a portable prothrombin time monitor by patients at home is feasible and provides accurate measurements. Patients doing home monitoring achieve superior anticoagulation control compared with those receiving standard anticoagulation clinic care.
评估在家监测凝血酶原时间的有效性和准确性。
随机、前瞻性队列研究。
从大学医院或社区医院出院的门诊患者。
50例首次开始使用华法林的患者,这些患者具备使用监测仪的能力且在医院内对华法林未达到稳定反应。
使用便携式凝血酶原时间监测仪管理口服抗凝治疗,并与专业抗凝门诊护理进行比较。
在完成8周研究的46例患者中,家庭监测组(n = 23)患者处于等于目标凝血酶原比值±0.3但始终高于1.25的范围内的时间中位数为93%,而门诊组(n = 23)患者为75%(P = 0.003)。两组在高于治疗范围的时间百分比方面无显著差异;然而,门诊组患者低于治疗水平的时间百分比显著更高(P < 0.001)。两组均未发生重大血栓栓塞或出血并发症。家庭监测测量值与在家庭检测后4小时内采集血样进行的相应临床实验室测量值之间的差异,与使用两种不同临床实验室仪器测量值之间观察到的差异相当。
患者在家使用便携式凝血酶原时间监测仪是可行的,且能提供准确测量结果。与接受标准抗凝门诊护理的患者相比,进行家庭监测的患者能实现更好的抗凝控制。